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Available online 27 May 2016Background: Using recombinant adeno-associated virus 2 (rAAV-2), we attempted to establish a HEK293T cell
line that is able to site-speciﬁcally integrate and stably express glial cell line-derived neurotrophic factor (GDNF).
Results: Recombinant vector with enhanced green ﬂuorescent protein (EGFP) and GDNF
(pTR-P5-EGFP-IRES-GDNF), as well as that carrying Rep genes and SV40 promoters (pSVAV2) were
constructed and packed. HEK293T cells were co-infected with rAAV-2/EGFP-GDNF and rAAV-2/SVAV2 virus
separately at 1 × 104, 1 × 105, and 1 × 106 of multiplicity of infection (MOI). The efﬁciency of transduction
was detected using ﬂow cytometry. Additionally, the infected HEK293T cells were separately validated by
touchdown polymerase chain reaction (PCR) and Western-blot. After 72 h of transduction, the rate of EGFP
positive cell was 22%, 45% and 49% at the MOIs of 1 × 104, 1 × 105 and 1 × 106, respectively. On the 3rd, 6th
and 9th day of cell passage, there was no signiﬁcant difference in the cell viability and proliferation rate
between transduction and control groups. Importantly, touchdown PCR showed that there was a speciﬁc PCR
ampliﬁed product band in the lane of infected cells. Furthermore, GDNF expression was detected in the
infected cells after 15 and 180 d of cultivation.
Conclusions: A HEK293T cell line able to site-speciﬁcally integrate and stably express GDNF was established.
© 2016 Pontiﬁcia Universidad Católica de Valparaíso. Production and hosting by Elsevier B.V. All rights reserved.Keywords:
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Transduction1. Introduction
Gene therapy is being used in treatment for multiple kinds of
inherited diseases [1,2]. By transferring viruses carrying genes of
interest into the target cells, gene therapy can result in an improvement
of the clinical status of a patient or even cure a disease [3]. Neurotrophic
factors are crucial for the development, function, and survival of
neurons. Glial cell line-derived neurotrophic factor (GDNF), a kind of
multiple efﬁcient neurotrophic factor separated from rat glioma cell line
B49 by Lin et al. [4], can activate the MAP kinase signaling pathway in
cultured sympathetic neurons and support the survival of sympathetic
neurons as well as sensory neurons of the nodose and dorsal root
ganglia [5]. Furthermore, GDNF is considered as the most potent
survival factor for motor neurons [6]. A recent study has shown that
GDNF is important for the differentiation of Schwann cells into their
native phenotype in order to improve functional nerve regeneration [7].
Therefore, GDNF is an ideal candidate gene for nerve injury and
neurodegenerative diseases.idad Católica de Valparaíso.
araíso. Production and hosting by ElAdeno-associated virus (AAV), a small single-stranded DNA virus, is
one of the four Parvoviridae family genera and has been the vector of
choice in recent clinical trials of neurological diseases [8,9]. AAV is able
to integrate into a speciﬁc site on human chromosome 19 (19q13.4),
which is known as AAVS1 [10]. Due to multiple advantages, including
high efﬁciency of transduction of postmitotic tissues in vivo, long-term
stable transgene expression and high security without inﬂammation
or immune response, AAV vectors and recombinant AAV (rAAV)
vectors have been widely applied to the establishment of transgenic
cell lines and gene therapy [11,12,13].
In this study, using rAAV-2 vector, we attempted to establish a stable
HEK293T cell line,which is able to site-speciﬁcally integrate and express
exogenous GDNF. The established stable cell line may contribute to the
further study of GDNF gene therapy.2. Materials and methods
2.1. Recombinant vector construction
Both pTR-P5-EGFP-IRES-GDNF and pSVAV2 recombinant plasmid
vectors [14] were constructed using standard molecular cloning
method [15]. The GDNF target gene of 738 bp was ampliﬁed bysevier B.V. All rights reserved.
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extracted using a QIAquick Gel Extraction kit (OMEGA Bio-Tek,
Doraville, USA) after Cla I digestion. Similarly, internal ribosome entry
site (IRES) sequence with a length of 695 bp was synthesized. Then,
Not I and Cla I Enzyme cutting sites were separately inserted into 5′
and 3′ ends of the IRES sequence. Subsequently, a gel fragment of
684 bp was extracted using a QIAquick Gel Extraction kit (OMEGA
Bio-Tek, Doraville, USA) after double digestion. After being connected
using DNA connection kit (TaKaRa, Tokyo, Japan), the connection
product of plasmid vector pTR-P5-EGFP (6297 bp), GDNF target gene
fragment and IRES sequence fragment were transferred to the
competent cells Sure-2 prepared and saved by our laboratory. Positive
clone was selected and cultivated. Afterwards, plasmids were extracted
using a Plasmid DNA Extract kit (Qiagen, Valencia, CA, USA) and
puriﬁed using a Plasmid DNA Puriﬁcation kit (Qiagen, Valencia, CA).
Then, recombinant intermediate plasmid pTR-P5-EGFP-IRES-GDNF was
validated by PCR and sequencing (sequenced by Sangon Biotech Co.,
Ltd., Shanghai, China) after digestion with Not I and Cla I (Takara,
Tokyo, Japan). Similarly, pSVRep carrying rep gene and SV40 prompter
were digested with EcoR V and Hind III (Takara, Tokyo, Japan), and
then it was inserted into pAV2 digested by BmgB I and Hind III (Takara,
Tokyo, Japan) to obtain recombinant intermediate plasmid pSVAV2.
After digestion, the recombinant plasmid was also validated by PCR
and sequencing (sequenced by Sangon Biotech Co., Ltd., Shanghai,
China).
2.2. Packing, puriﬁcation and identiﬁcation of recombinant virus
According to the molar ratio of 1:1 (N/P = 20), pTR-P5-
EGFP-IRES-GDNF and pSVAV2 were separately co-infected with pDG
into HEK293T cells using the calcium phosphate coprecipitation
method [16]. Thus, rAAV-2/EGFP-GDNF and SVAV2 viruses were
synthesized, respectively. Then, viruses were puriﬁed and
concentrated by the method of cesium chloride gradient
centrifugation [17]. In addition, titers of rAAV-2/EGFP-GDNF and
rAAV-2/SVAV2 recombinant virus solutions were measured by
ﬂuorescent quantitative PCR in an ABI 7500 Real-Time PCR system
(Applied Biosystems, USA), respectively, using a ﬂuorescence
quantitative PCR kit (Tiangen Biotech Co. Ltd., Beijing, China). The PCR
program was followed as follows: 94°C for 20 s, 40 cycles of 95°C for
3 s and 60°C for 40 s.
2.3. Recombinant virus transduction
HEK293T cells purchased from cell bank of Typical culture
preservation commission, Chinese academy of sciences, were cultured
in 24-well plates ﬁlled with 90% Dulbecco's modiﬁed eagle medium
(DMEM, Gibco, Grand Island, NY, USA) supplemented with 10% Fetal
Bovine Serum (FBS, Gibco, Grand Island, NY, USA). When the cells
spread to 70–80% of the plate, the culture solution was removed, and
200 μL DMEM containing 2% FBS was added to the plates. Then,
rAAV-2/EGFP-GDNF and rAAV-2/SVAV2 (rAAV-2/EGFP-GDNF:rAAV-2/
SVAV2 = 50:1) recombinant virus was added to the new media with
the multiplicity of infection (MOI) of 0, 1 × 104, 1 × 105 and 1 × 106,
respectively. MOI = 0 was taken as non-transduction control group.
After 24 h of transduction in a humidiﬁed 5% CO2 incubator (Thermo
Scientiﬁc BB150, USA) at 37°C, EFGP expression was observed and
recorded under an inverted ﬂuorescence microscope (ZEISS, Shanghai,
China). When EGFP expression was stable after 72 h of transduction,
the transduction efﬁciency of rAAV-2/EGFP-GDNF to HEK293T cell was
detected by a LSRFortessa ﬂow cytometer, equipped with 405 nm,
488 nm, 561 nm and 640 nm lasers (Becton Dickinson, CA, USA). The
cells received a passage every three days. On the 3rd, 6th and 9th day
of cell passage, cell viability was tested using trypan blue stain assay
[18] and calculated as follows: amount of viable cells / (amount of
viable cells + amount of dead cells) × 100%; meanwhile, cellproliferation rate was counted for each group as follows: amount of
viable cells on the 3rd, 6th or 9th day/amount of viable cells of
original culture.
2.4. Screening and identiﬁcation of the stable cell line
The infected HEK293T cells expressing EGFP were separated by the
LSRFortessa ﬂow cytometer and separately cultivated in 96-well plates
ﬁlled with 90% DMEM with 10% FBS. The cell culture media were
changed every two days. When the cells spread to 80% of the plate,
they were transferred to 24-well plates to expand the culture dose
and establish cell lines for identiﬁcation. Then, nuclear DNA of the
infected HEK293T cells was extracted using a DNeasy blood and tissue
Kit (Cat. No. 69504; QIAGEN, Valencia, CA, USA). Meanwhile, the DNA
of non-infected HEK293T cells was extracted as control. Touchdown
PCR was conducted using a Biometra PCR machine (Biometra,
Germany). The speciﬁc primer pairs used are AAV D-sequence sense
primer HAIJP1 (5′-AGGAACCCCTAGTGATGGAG-3′) and human
chromosome 19 AAVS1 site-speciﬁc primer HAIJP2 (5′-TCAGAGGACA
TCACGTGGTG-3′) [14] which were synthetized by Sangon Biotech Co.,
Ltd. (Shanghai, China), and the program was detailed as follows: 94°C
for 2 min, 5 cycles of 98°C for 10 s and 74°C for 30 s, 5 cycles of 98°C
for 10 s and 72°C for 30 s, 5 cycles of 98°C for 10 s and 70°C for 30 s,
30 cycles of 98°C for 10 s and 68°C for 30 s, as well as 68°C for 7 min.
The enzyme used in PCR was KOD-Plus-Neo enzyme (Toyobo
Life Science Co., Ltd., Tokyo, Japan). After PCR ampliﬁcation,
electrophoresis on 1% agarose gel was conducted to detect whether
pTR-P5-EGFP-IRES-GDNF had been integrated into AAVS1 locus in
human chromosome 19. After 15 and 180 d of cultivation, the
screened infected cells were collected and then tested using standard
Western-blot as described previously by Ausubel et al. [19], to identify
whether they had GDNF or not. The blots were probed with rabbit
anti-GDNF (1:500; Santa Cruz, USA) and horseradish peroxidase
(HRP)-conjugated goat anti-rabbit (1:10,000; Abgent, USA) antibodies.
2.5. Statistical analysis
The experimental data were expressed by mean ± standard
deviation (SD). The one-way analysis of variance (ANOVA) was used
to conduct comparison among groups and the SPSS 21.0 software was
applied to perform statistical tests on the experimental data. The
P b 0.05 was regarded as statistically signiﬁcant.
3. Results
3.1. Vector construction and titer determination
After GDNFwas digested by Cla I, aswell as IRESwas digested byNot
I and Cla I, they were linked to pTR-P5-EGFP vector, which produced
pTR-P5-EGFP-IRES-GDNF recombinant vector (7703 bp) (Fig. 1a).
Meanwhile, pSVRep was digested by EcoR V and Hind III,
subsequently, it was linked to pAV2 digested by BmgB I and Hind III to
obtain pSVAV2 recombinant vector (8669 bp) (Fig. 1b). Positive clones
were examined by colony PCR, and DNA sequencing after digestion
declared that GDNF and pSVRep were separately integrated into
the pTR-P5-EGFP vector and the pAV2 vector (Fig. 1d). The
pTR-P5-EGFP-IRES-GDNF and pSVAV2 were respectively co-infected
with pDG into HEK293T cells, after 48 h, most of the cells showed
EGFP expression (Fig. 1c). Titers of rAAV-2/EGFP-GDNF and SVAV2
recombinant virus solutions were 1 × 1012 vg/mL and 8 × 1011 vg/mL,
respectively.
3.2. Efﬁciency of transduction
To investigate the transduction efﬁciency of the recombinant
virus, HEK293T cells were infected at different MOIs (1 × 104, 1 × 105
Fig. 1.Vector construction (bars: 100 μm). (a) Schematic representation of pTR-P5-EGFP-IRES-GDNF recombinant vector. (b) Schematic representation of pSVAV2 recombinant vector. (c)
Expression of EGFP in HEK293T cells observed under a ﬂuorescencemicroscope. (d) Electrophoresis result of colony PCR products for pTR-P5-EGFP-IRES-GDNF and pSVAV2 recombinant
vector. Lane M: DNA marker; Lane 1: pTR-P5-EGFP-IRES-GDNF; Lane 2: pSVAV2.
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HEK293T cells was measured using ﬂow cytometer to assess
transduction efﬁciency. The rate of EGFP positive cells at the MOIs of
1 × 105 and 1 × 106 was 45% (Fig. 2b) and 49% (Fig. 2c), respectively,Fig. 2. Fluorescencemicroscopic images of EGFP expression after 24 h of transduction (bars: 100
cells with the ratio of rAAV-2/EGFP-GDNF to rAAV-2/SVAV2 at 50:1 when MOI was 1 × 104 (awhereas just 22% (Fig. 2a) of the cells were EGFP positive at the MOI
of 1 × 104. In addition, there was no signiﬁcant difference of the cell
viability and proliferation rate between the transduction groups and
the control group (P b 0.05) (Table 1).μm) and ﬂow cytometry results of EGFP expression after 72 h of transduction in HEK293T
), 1 × 105 (b) and 1 × 106 (c), respectively.
Table 1
The cell viability and proliferation rate between the transduction groups and the control group (when cultivated for 3, 6 and 9 d).
Groups Cell viability (%) Proliferation rate
3 d 6 d 9 d 3 d 6 d 9 d
MOI = 0 96.07 ± 1.61 96.01 ± 1.21 96.22 ± 1.35 8.35 ± 0.14 24.46 ± 0.28 42.40 ± 0.21
MOI = 1 × 104 96.24 ± 1.65 96.26 ± 1.22 96.10 ± 1.22 8.37 ± 0.20 24.38 ± 0.19 41.18 ± 1.09
MOI = 1 × 105 96.38 ± 1.64 96.33 ± 1.31 96.18 ± 1.34 8.42 ± 0.23 24.35 ± 0.26 41.30 ± 1.10
MOI = 1 × 106 96.05 ± 1.68 96.09 ± 1.42 96.01 ± 1.58 8.39 ± 0.12 24.29 ± 0.25 42.40 ± 0.85
Note: All the transduction groupswere comparedwith the control group at the same time. Cell viability was calculated as follows: amount of viable cells (amount of viable cells + amount
of dead cells) × 100%; cell proliferation rate was counted for each group as follows: amount of viable cells on the 3rd, 6th or 9th d/amount of viable cells of original culture.
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The infected HEK293T cells expressing EGFPwere separated by ﬂow
cytometry ﬂuorescence instrument, and cell strains for identiﬁcation
were established. The ﬂuorescent expression of monoclonal cell strain
was seen under ﬂuorescence microscope (Fig. 3a). Meanwhile, the
rate of ﬂuorescent cell was 99.7% when tested with FCM (Fig. 3b),
which proved that cell lines integrated with exogenous genes were
successfully established. Then, cells were collected and nuclear DNA
was extracted. Afterwards, touchdown PCR was conducted, and only
in the lane of the infected cells, a distinct PCR ampliﬁed product band
(1000 bp) was detected, but there was not in the lane of the
non-infected cells (Fig. 4). According to the Western-blot test, there
was a distinct electrophoretic band in the lanes of the infected cells
after 15 and 180 d of cultivation, respectively (Fig. 5).
4. Discussion
GDNF is an ideal candidate gene for the therapy of nerve injury and
neurodegenerative diseases [20]. In this study, to establish a stable cell
line able to express GDNF, rAAV-2 vector was used for the delivery
of GDNF into HEK293T cells. A recombinant vector carrying EGFP
and GDNF (pTR-P5-EGFP-IRES-GDNF), as well as pSVAV2 were
constructed. Afterwards, they co-infected HEK293T cells at different
MOIs, and cell viability and proliferation rate were calculated. Besides,
the stable infected cells were screened and validated by touchdown
PCR and Western-blot.
Results showed that the rate of EGFP-positive cells at the MOIs
of 1 × 105 and 1 × 106 was obviously higher than that at the MOI
of 1 × 104. Transduction of AAV-2 into target cells was mediated
by heparan sulfate proteoglycan, which is a type of cell-surface
receptor [21]. Thus, efﬁciency of transduction enhanced along with
the enlargement of MOI before binding between rAAV-2 and its
receptor reached equilibrium. When binding between rAAV-2 and its
receptor achieved a balance, efﬁciency of transduction was no longerFig. 3. Fluorescence microscopic image of EGFP expression in HEK293T cells (bars: 100 μm)of obvious enhancement along with the ampliﬁcation of MOI. These
declared that 1 × 105 was the optimal MOI.
Furthermore, on the 3rd, 6th and 9th d of cell passage, there was no
signiﬁcant difference of the cell viability and proliferation rate between
the transduction groups and control group, indicating that after
infection of rAAV-2 vector, the cell viability and proliferation rate of
HEK293T cells were still stable. A similar result was previously
reported by Yoshioka et al. [22]. The stable cell viability and
proliferation rate are likely due to the high biosafety of rAAV-2 vector
[23,24]. Besides, in each group, the cell viability was stable (keeping
about 96%) over time after transduction, indicating that the difference
of MOI was not an inﬂuential factor of cell viability and proliferation
after transduction. Taken together, it proved that the survivability of
HEK293T cells was not affected by the transduction of rAAV-2 vector
carrying GDNF.
In this study, the touchdown PCR assay showed that pTR-P5-
EGFP-IRES-GDNF had been integrated into AAVS1 locus on human
chromosome 19. AAVS1 locus is a speciﬁc site that can be integrated
by AAV [10]. A previous study reported by us has demonstrated that
rAAVSVAV2 carrying green ﬂuorescent protein (GFP) gene is able to
integrate at AAVS1 locus on chromosome 19 in the HeLa cell genome,
and GFP is expressed stably for 35 passages [14]. Additionally, there
was GDNF expression in the infected cells after 15 and 180 d of
cultivation, suggesting that GDNF was expressed for a long time in
HEK293T cells. A similar study has used a rAAV-GDNF vector to
express GDNF long-term (6 months) nigral dopamine neurons and
striatal target cells [25]. These results demonstrated that rAAV is a
highly efﬁcient vector system for long-term expression of GDNF.
Previous studies on gene therapy of nervous system diseases have
used lentiviral vectors [26], AAV2 [27] or AAV5 [28] for GDNF delivery
into eukaryotic cells. Compared with AAV vectors, lentiviral vectors
have a large cloning capacity, whereas, they can integrate into the cell
genomes, which are highly favorable for long-term expression of
transgenes in the nervous system, but meanwhile it raises a set of
important safety issues that may limit their clinical use [29]. Both(a) and the rate of EGFP positive cells (b) after cultivation for 180 d. MOI used is 1 × 105.
Fig. 4. Electrophoresis result of touchdown PCR products of DNA from infected HEK293T
cells. Lane M: DNA marker; Lane 1: touchdown PCR products of DNA from non-infected
HEK293T cells; Lane 2: touchdown PCR products of DNA from infected HEK293T cells.
MOI used is 1 × 105.
79J. Zhang et al. / Electronic Journal of Biotechnology 22 (2016) 75–80AAV2 and AAV5 have a highly effectivity in the delivery of its transgene
into nerve cells and have been widely used for the gene therapy study.
However, by contrast, rAAV vectors have a higher biosecurity due to
the removement of 96% of viral genome [29], and they are considered
as the most promising and commonly-used vectors in gene therapy
research. Therefore, in this study, rAAV2-mediated GDNF transfer in
HEK293T cells is promising in the application of further clinical study.
We can use this HEK293T cell line to extract GDNF, and purify it for
the application of further GDNF-related studies, such as gene therapy
for nerve injury and neurodegenerative diseases.
Despite the aforementioned results, this study has several
limitations. For example, the GDNF expression in the infected cells
needs to be detected quantiﬁcationally. The Rep and Cap expression in
the infected cells should have been determined. In our further study,
we will solve these issues.
In conclusion, a cell line able to stably express GDNFwas established
using rAAV-2, and the HEK293T cell line was expected to be applied to
further GDNF-related studies, such as gene therapy for nervous
system diseases.Fig. 5. GDNF expression in the infected HEK293T cells after 15 and 180 d of cultivation,
respectively. Lane 1: GDNF expression in the infected HEK293T cells after 15 d of
cultivation; Lane 2: GDNF expression in the infected HEK293T cells after 180 d of
cultivation; Lane 3: GDNF expression in the non-infected normal HEK293T cells. MOI
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